Icelandic Fish-Skin Wound Care Manufacturer Acquired by Coloplast for $1.3 Billion

Coloplast has signed a $1.3 billion agreement to acquire Kerecis, a biologics wound care manufacturer based in Iceland, with an FDA-cleared patented technology platform based on intact fish skin.

Kerecis’s products are “sustainably produced using fish skin, a by-product from Icelandic fisheries, and 100% green energy” Coloplast said in its announcement of the acquisition, noting that more than two-thirds of Kerecis’s 500 employees are located in the company’s production facility close to the Arctic Circle.

“Produced with minimal processing, the fish skin retains its similarity to human skin, resulting in improved wound healing,” the company said, adding that the product, primarily used in hospitals, has already been used to treat more than 20,000 patients.

After the expected acquisition, Coloplast says Kerecis “will operate as a stand-alone business unit under its own identity and brand.”

To read the full story, click here to subscribe.

Related Topics